REVISE
Clinical signs of Raised ICP
ICP Control: Tiered System
(J Clin Med, 2022)
A stepwise system for management of ⬆️ ICP where Tt modalities used are prioritised based on their efficacy and relative risks.
Safer Tt- lower tiers
Tt with significant SE- higher tiers.
🟢 Tier Zero – Initial ICU Management
i* Admit to ICU
ii* Stabilisation & evaluation:
iii* Airway support: I & V
iv* Sedation & analgesia ( for comfort, facilitate MV)
v* Seizure prophylaxis, monitoring (Art line, CVC, ICP, etc.)
vi* Avoid Hypotension, ⬇️Na, ⬆️thermia
vii* Serial clinical evaluations
viii* Optimise venous return
=>Targets:
* SpO₂ > 94%
* PaCO₂ 35–38 mmHg
* MAP 80–100 mmHg
* CPP 60–70 mmHg
* Temp < 38°C
Revise
🟡 Tier One – Escalation for ICP Control
I) Sedation & analgesia- for ICP control
2) PaCO₂: Maintain low-normal (35–38 mmHg)
3) CSF drainage via EVD
- -CPP-60-70mm hg
4) Osmotherapy:
* Mannitol or hypertonic saline (e.g., 3% NaCl)
-Maint. se osmolarity- 320mosm/kg,
Se Na- 155mmol/L
5) Seizure prophylaxis
6) Consider EEG monitoring
🟠 Tier Two – If ICP Refractory to Tier One
Hypocapnia carries risk of cerebral ischemia
🔴 Tier Three – Rescue Therapy
BTF Recommendations
=> Maintain ICP < 22 mmHg
=> Maintain CPP > 60 mmHg
Intracranial Hypertension (ICH) in TBI
-common complication of TBI
- Associated with significant morbidity & mortality
Tiered System Approach
Advantages of Tiered System
II. May identify:
* Extracranial causes of raised ICP:
* Infection
* Respiratory deterioration
* Seizure
* Other medical disorders
III. Imaging might show:
* Lesions amenable to surgery or evacuation
* Avoiding unnecessary medical escalation
IV. Flexible Decision-Making
* Allows skipping or individualising therapy tiers
* Can omit a tier if next step more beneficial
Tier One Therapies – Side Effects
=> Osmotherapy: Both Mannitol & Hypertonic Saline may:
* Cause fluid and electrolyte derangements
=> EVD drainage: Prefer ICP-guided drainage, not scheduled/protocolised
* ⚠️ In significant brain edema, drainage can be:
- Technically difficult
-↑ risk of hemorrhage or misplacement
Tier Two Therapy Considerations
I]. Mild Hypocapnia
=>Mild Hypocapnia (PaCO₂: 32–35 mmHg)
I)* Causes cerebral vasoconstriction → ↓ CBF
* Risk of focal cerebral ischemia
* If used, should be:
->Multimodally monitored using:
-> Global & focal cerebral O2 monitoring
> TCD
> SjvO₂
>PbtO₂
* ⚠️ Not widely available in all ICUs
II)* Raised pH →
-↓ blood flow to tissues
- Electrolyte derangements:
(↓ K⁺, ↓ Ca²⁺, ↓ PO₄³⁻)
-↑ risk of seizures
III)* Since CBF is lowest in first 24 hours post-injury: reasonable to avoid hypocapnia during this period
=>* CO2 < 30 mmHg:
* ⚠️ Only to be used temporarily as a bridge (e.g. before surgery)
* Examples:
- Cushing’s reflex
-Impending herniation
* Once stabilized, gradual return to normocapnia is critical–> Prevents rebound intracranial hypertension
Neuromuscular Blockade (NMB) in ⬆️ ICP
Indications
Advantages
Disadvantages
=>Advantages:
* May lower ICP by 2–3 mmHg
* ↓ Ventilator asynchrony–> Improved venous return from thoracic vessels- may improve MAP–>CPP
=> Drawbacks:
↑ Risk of:
* Ventilator-associated pneumonia (VAP)
* ICU-acquired neuromuscular weakness (e.g. ICU myopathy)
* Prolonged ICU stay
✅** Indications for NMB:**
*⬆️ ICP not responding to TIER 1therapies
* Severe ARDS or lung contusion
* Abdominal compartment syndrome
* Procedures:
- Bronchoscopy
-Tracheal suctioning
*Hyperthermia due to ↑ CO₂ production (from excess muscle activity)
SPAR – Static Pressure Autoregulation Assessment
✅ Method:
* Record baseline MAP, ICP, and CPP
* Stabilise CPP at ≥ 60 mmHg
* Titrate vasopressors to increase MAP by **10mm hg –>Observe ICP response for a maximum of 20mins. **
⬆️MAP–> ⬆️ CPP–> Cerebral vasoconstriction–> ⬇️CBF–> ⬇️Cerebral Bld volume –> ⬇️ ICP
Interpretation:
* ↑ ICP with ↑ MAP → cerebral vasoconstriction fails → poor autoregulation mmHg
If autoregulation is intact- ⬆️ MAP via fluids/Vasopressors
=>Limitations:
* ICP may rise exponentially if SPAR is lost
* MAP elevation may be difficult (esp. trauma, myocardial injury, high baseline)
* SPAR status can change → requires repeat assessment
🔴 Tier 3 Therapy –
Therapeutic Hypothermia
Q. Mechanism
Q. Cellular level effects
Q. Risks
💡 Mechanism: Target temp** 35- 36°C** (esp. brain temp)
* ↓ Metabolic demand
* ↓** Brain tissue inflammation
🔬 Cellular-level effects:
* ↓ Excitotoxicity
* ↓ Inflammatory response
* ↓ Cerebral edema (esp. cytotoxic edema)
⚠️ Risks of Hypothermia * Pneumonia * Cardiovascular complications: * Arrhythmias * ↓ cardiac output * Coagulation dysfunction * Platelet impairment
Hypothermia cont..
Q. Evidence regarding Mild hypothermia
Q. Current recommendations
=> Clinical Trial Outcomes
* No mortality benefit seen in large RCTs
–>Eurotherm- stopped early due to Safety concerns
–> POLAR - No improvement in clinical outcomes
✅ Current Recommendation * Mild hypothermia only * Target temp: 35–36°C * <35°C is not recommended
Compared to other Tier 3 therapies Hypothermia may be more suitable for
* Patients not actively bleeding
* Not surgical candidates eg- medically managed ICP without craniectomy
Barbiturates in TBI
Q. Common agents used
Q. Mechanism of action in TBI
Q. Adverse effects
=>Common Agents:
* Thiopentone
* Phenobarbital
=>Mechanism: * Induce greater metabolic suppression vs. propofol/midazolam * Also possess: - Antiepileptic properties$ - Neuroprotective effects (↓ cerebral metabolic demand, ↓ excitotoxicity) $
=>Adverse Effects of Barbiturates
* Hypotension, myocardial depression
* Often requires vasopressors to maintain CPP
* Immunosuppression
* Hepatic and renal dysfunction
* Hypokalemia (esp. during loading phase)
* Hyperkalemia during withdrawal (May become severe enough to need RRT)
* Suppressed pupillary light reflex
* ⚠️ Can mimic brainstem herniation → need for neuro exam via EEG
* Drug accumulation->Prolonged sedation → delayed extubation, prolonged ICU stay
Barbiturates in TBI cont..
Q. How will you initiate barbiturate coma in TBI?
Q.** What are the goals of therapy?
Q. What is the End Point?
Q. How will you withdraw Barbiturate therapy?**
=>Initiating Barbiturate Therapy
💉 Dosing
* Test dose of thiopentone (250 mg bolus)
* Assess ICP response
* If ICP ⬇️es with maintainence of CPP→ continue
* Total bolus dose: ~3–5 mg/kg(max-5g)
* Continuous infusion: 3–8 mg/kg/hr
*EEG monitoring recommended
⸻
🎯 End Point
* Aim for burst suppression ≥ 50% on EEG
* Used to assess depth of metabolic suppression
⸻
Goals of Therapy
* Achieve ICP control with minimum effective dose
=>Maintain:
* Euvolemia
* Adequate CPP
⸻
⚠️ Withdrawal Strategy
* Gradual reduction over a few days to prevent rebound ICP increase
Decompressive Craniectomy (DC)
Q. Indications
Q. Risks and Complications
Q. Evidence
=> Used for refractory ICP elevation
=>Indications: Ideal Candidates for DC
* Previously fit individuals
* Unilateral pathology
* Good medical and social support
* Early phase of illness
* Non-responders to other treatments
In Limited Resource Settings where advanced monitoring (e.g., ICP, EEG, PbtO₂) is not available:
* Use of basic measures such as:
- Scheduled hyperosmolar therapy
-Continuous infusion of 3% saline
* Surgical options may be central to management
Barbiturates vs Propofol / Midazolam
=>Barbiturates provide:
* More effective suppression of cerebral O₂ consumption.
* Better reduction in metabolic demand
* Neuroprotective advantages
=>Propofol disadvantages (especially in high doses): * Cardiovascular depression * Pancreatitis, lipemia, PRIS (Propofol Infusion Syndrome) * Hepatic dysfunction, Transaminitis * Rhabdomyolysis, renal failure * Malignant arrhythmias * Cardiovascular collapse * Thought to be due to impaired mitochondrial function & lipid metabolism
DC cont..
Q. Complications
Q. Evidence
Complications of Decompressive Craniectomy
* Infection
* Bleeding
* Transtentorial herniation
* Hydrocephalus
* Subdural hygroma
⚠️ Risks should be explained clearly to the patient’s family before the procedure.
DC cont..
Q. Evidence
🔬 Trial Summaries:
Use of Tiered approach
**Use of the tiered approach:
i) When possible, use the lowest tier
ii) Move to the next tier if the ICP remains raised (CPP below 60-70)
iii) It is not necessary to use all the modalities within a tier before moving to the next tier
iv) Tiers can be skipped if this is considered advantageous
**